State Street’s TriSalus Life Sciences TLSI Stock Holding History

State Street’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31M	Buy	328,020 +63,392	+24%	+$310K	﹤0.01%	3425
2025 Q4	$1.85M	Buy	264,628 +71,995	+37%	+$403K	﹤0.01%	3365
2025 Q3	$896K	Buy	192,633 +77,036	+67%	+$361K	﹤0.01%	3537
2025 Q2	$630K	Buy	115,597 +95,397	+472%	+$512K	﹤0.01%	3574
2025 Q1	$112K	Hold	20,200	–	–	﹤0.01%	3951
2024 Q4	$101K	Buy	20,200 +9,100	+82%	+$38.5K	﹤0.01%	3985
2024 Q3	$51.2K	Hold	11,100	–	–	﹤0.01%	4094
2024 Q2	$61.3K	Buy	+11,100	New	+$94.1K	﹤0.01%	4111
2022 Q1	–	Sell	-11,409	Closed	-$113K	–	4926
2021 Q4	$113K	Buy	+11,409	New	+$113K	﹤0.01%	4552

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

State Street's TLSI Position: Q1 2026 in Review

State Street increased its TriSalus Life Sciences (TLSI) stake by 24% in Q1 2026, buying an estimated $310K and bringing the position to 328,020 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

State Street first reported a position in TLSI in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.85M in Q4 2025. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

State Street held 328,020 shares of TriSalus Life Sciences worth $1.31M as of Q1 2026.
State Street bought 63,392 TriSalus Life Sciences shares in Q1 2026, an estimated $310K.
TriSalus Life Sciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3425 holding.
State Street first reported a position in TriSalus Life Sciences in Q4 2021 and has held it in 9 quarters since.
State Street's TriSalus Life Sciences position peaked at $1.85M in Q4 2025.
84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.